Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Conditions
Interventions
Dexamethasone
Lenalidomide
+1 more
Locations
127
United States
Mayo Clinic
Scottsdale, Arizona, United States
Providence St. Joseph Medical Center
Burbank, California, United States
St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare
Santa Rosa, California, United States
Stanford University
Stanford, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Cancer and Blood Disease Center
Lecanto, Florida, United States
Start Date
July 14, 2010
Primary Completion Date
June 16, 2014
Completion Date
December 5, 2017
Last Updated
September 21, 2022
NCT06952478
NCT04434469
NCT04119336
NCT04802031
NCT03716856
NCT01949532
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions